{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:49:57Z","timestamp":1793332197675,"version":"4.5.0"},"reference-count":127,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/100012569","name":"The University of Toledo","doi-asserted-by":"publisher","award":["N-127483-01"],"award-info":[{"award-number":["N-127483-01"]}],"id":[{"id":"10.13039\/100012569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2020,8,17]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Parkinson\u2019s Disease (PD) is a neurodegenerative disease involving degeneration of dopaminergic\nneurons of the nigrostriatal pathways. Over the past decades, most of the medications for the\ntreatment of PD patients have been used to modulate dopamine concentrations in the basal ganglia.\nThis includes levodopa and its inhibitory metabolizing enzymes. In addition to modulating dopamine\nconcentrations in the brain, there are D2-like dopamine receptor agonists that mimic the action of dopamine\nto compensate for the deficit in dopamine found in PD patients. Muscarinic antagonists\u2019 drugs\nare used rarely due to some side effects. Monoamine oxidase inhibitors are among the first in line, and\nare considered popular drugs that reduce the metabolism of dopamine in PD patients. Furthermore, we\ndiscussed in this review the existence of certain glutamate receptor antagonists for the treatment of\nPD. Alternatively, we further discussed the potential therapeutic role of adenosine (2A) receptor antagonists,\nsuch as tozadenant and istradefylline in the treatment of PD. We also discussed the important\nrole of serotonin1A receptor agonist, adrenergic autoreceptors (&amp;#945;2) antagonists and calcium\nchannel blockers in the treatment of PD. Finally, neurotrophic factors, such as glial cell line-derived\nneurotrophic growth factor and brain-derived neurotrophic factor are considered the primary factors\nfor neuroprotection in PD.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871527319666200525011110","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T06:14:43Z","timestamp":1590387283000},"page":"195-206","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Overview of Therapeutic Drugs and Methods for the Treatment of Parkinson\u2019s Disease"],"prefix":"10.2174","volume":"19","author":[{"given":"Andrew","family":"Schneider","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam T.","family":"Sari","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Alhaddad","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Sari","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"504","volume":"40(8)","author":"DeMaagd,G.","year":"P&T 2015","unstructured":"DeMaagd,G.; Philip,A. Parkinson\u2019s disease and its management: part. 1: disease entity, risk factors, pathophysiology, clinical presen-tation, and diagnosis. P&T 2015; 40(8): 504-32. PMID: 26236139"},{"key":"ref=2","author":"Armstrong,MJ.","unstructured":"Armstrong,MJ.; Okun,MS. Diagnosis and treatment of Parkinson\u2019s disease: a review,J. AMA 2020; 323(6): 548-60. http:\/\/dx.doi.org\/10.1001\/jama.2019.22360 PMID: 32044947.","journal-title":"AMA"},{"key":"ref=3","first-page":"44","volume":"23(1)","author":"Athulya,RT.","year":"2020","unstructured":"Athulya,RT.; Jayakrishnan,S.; Iype,T.; Rajan,R.; Alapatt,PJ. Predic-tors of levo-dopa induced dyskinesias in Parkinson\u2019s disease. Ann Indian Acad Neurol. 2020; 23(1): 44-7. PMID: 32055121","journal-title":"Ann Indian Acad Neurol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1212\/WNL.41.2_Part_1.202","volume":"41(2 (Pt 1) )","author":"Kostic,V.","year":"1991","unstructured":"Kostic,V.; Przedborski,S.; Flaster,E.; Sternic,N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson\u2019s disease. Neurology. 1991; 41(2 (Pt 1) ): 202-5. http:\/\/dx.doi.org\/10.1212\/WNL.41.2_Part_1.202 PMID: 1992362","journal-title":"Neurology"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/npp.2011.212","volume":"37(1)","author":"Smith,Y.","year":"2012","unstructured":"Smith,Y.; Wichmann,T.; Factor,SA.; DeLong,MR. Parkinson\u2019s dis-ease therapeutics: new developments and challenges since the in-troduction of levodopa. Neuropsychopharmacology. 2012; 37(1): 213-46. http:\/\/dx.doi.org\/10.1038\/npp.2011.212 PMID: 21956442","journal-title":"Neuropsychopharmacology"},{"key":"ref=6","doi-asserted-by":"publisher","author":"Gallagher,DA.","unstructured":"Gallagher,DA.; Lees,AJ.; Schrag,A. What are the most important nonmotor symptoms in patients with Parkinson\u2019s disease and are we missing them? Mov Disord. 2010; 25(15): 2493-500. http:\/\/dx.doi.org\/10.1002\/mds.23394 PMID: 20922807","DOI":"10.1002\/mds.23394"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/ana.410320616","volume":"32(6)","author":"Fahn,S.","year":"1992","unstructured":"Fahn,S.; Cohen,G. The oxidant stress hypothesis in Parkinson\u2019s disease: evidence supporting it. Ann Neurol. 1992; 32(6): 804-12. http:\/\/dx.doi.org\/10.1002\/ana.410320616 PMID: 1471873","journal-title":"Ann Neurol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351(24)","author":"Fahn,S.","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I.;et al. Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med. 2004; 351(24): 2498-508. http:\/\/dx.doi.org\/10.1056\/NEJMoa033447 PMID: 15590952","journal-title":"N Engl J Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s00702-018-1876-2","volume":"125(11)","author":"Riederer,P.","year":"2018","unstructured":"Riederer,P.; M\u00fcller,T. Monoamine oxidase-B inhibitors in the treatment of Parkinson\u2019s disease: clinical-pharmacological aspects. J Neural Transm (Vienna). 2018; 125(11): 1751-7. http:\/\/dx.doi.org\/10.1007\/s00702-018-1876-2 PMID: 29569037","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1212\/WNL.53.2.364","volume":"53(2)","author":"Korczyn,AD.","year":"1999","unstructured":"Korczyn,AD.; Brunt,ER.; Larsen,JP.; Nagy,Z.; Poewe,WH.; Ruggieri,S. A 3-year randomized trial of ropinirole and bromocriptine in ear-ly Parkinson\u2019s disease. The 053 Study Group. Neurology. 1999; 53(2): 364-70. http:\/\/dx.doi.org\/10.1212\/WNL.53.2.364 PMID: 10430427","journal-title":"The 053 Study Group.Neurology"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/mds.870130111","volume":"13(1)","author":"Rascol,O.","year":"1998","unstructured":"Rascol,O.; Brooks,DJ.; Brunt,ER.; Korczyn,AD.; Poewe,WH.; Stocchi,F. Ropinirole in the treatment of early Parkinson\u2019s disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord. 1998; 13(1): 39-45. http:\/\/dx.doi.org\/10.1002\/mds.870130111 PMID: 9452324","journal-title":"056 Study Group.Mov Disord"},{"key":"ref=12","author":"Reichmann H","unstructured":"Reichmann H. Long-term treatment with dopamine agonists in idiopathic Parkinson's disease J Neurol. 2000; 247 Suppl. 4: IV\/17-9","journal-title":"2000; 247 Suppl"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/1531-8257(199909) 14:5<725::AID-MDS1003>3.0.CO.;-L","volume":"14(5)","author":"Montastruc,JL.","year":"1999","unstructured":"Montastruc,JL.; Rascol,O.; Senard,JM. Treatment of Parkinson\u2019s disease should begin with a dopamine agonist. Mov Disord. 1999; 14(5): 725-30. http:\/\/dx.doi.org\/10.1002\/1531-8257(199909) 14:5<725::AID-MDS1003>3.0.CO.;-L PMID: 10495032","journal-title":"Mov Disord"},{"key":"ref=14","first-page":"317","volume":"11(6)","author":"Micieli,G.","year":"1996","unstructured":"Micieli G, Martignoni E, Cavallini A.;et al. Lisuride and bromo-cryptine in L-Dopa stable-responder parkinsonian patients: a com-parative, double-blind evaluation of cardiopressor and neurochemi-cal effects. Funct Neurol. 1996; 11(6): 317-25. PMID: 9074912","journal-title":"Funct Neurol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2147\/NDT.S60061","volume":"10","author":"Thorlund,K.","year":"2014","unstructured":"Thorlund,K.; Wu,P.; Druyts,E.; Ea,pen,S.; Mills,EJ. Nonergot dopa-mine-receptor agonists for treating Parkinson\u2019s disease-a network meta-analysis. Neuropsychiatr Dis Treat. 2014; 10: 767-76. http:\/\/dx.doi.org\/10.2147\/NDT.S60061 PMID: 24855362","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/pds.4986","volume":"29(5)","author":"Gungabissoon,U.","year":"2020","unstructured":"Gungabissoon,U.; Kirichek,O.; El Ba,ou,C.; Galwey,N. Comparison of long-term use of prolonged-re lease ropinirole and immediate-release dopamine agonists in an observational study in patients with Parkinson\u2019s disease. Pharmacoepidemiol Drug Saf. 2020; 29(5): 591-8. http:\/\/dx.doi.org\/10.1002\/pds.4986 PMID: 32153056","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=17","author":"Rewane,A. .","unstructured":"Rewane,A.; Nagalli,S. Ropinirole. Treasure Island, FL StatPearls 2020.","journal-title":"Treasure Island, FL StatPearls 2020"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1177\/106002809703101014","volume":"31(10)","author":"Gottwald,MD.","year":"1997","unstructured":"Gottwald,MD.; Bainbridge,JL.; Dowling,GA.; Aminoff,MJ.; Alldredge,BK. New pharmacotherapy for Parkinson\u2019s disease. Ann Pharmacother. 1997; 31(10): 1205-17. http:\/\/dx.doi.org\/10.1177\/106002809703101014 PMID: 9337447","journal-title":"Ann Pharmacother"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0014-4886(03) 00250-4","volume":"184(1)","author":"Bibbiani,F.","year":"2003","unstructured":"Bibbiani F, Oh JD, Petzer JP.;et al. A2A antagonist prevents do-pamine agonist-induced motor complications in animal models of Parkinson\u2019s disease. Exp Neurol. 2003; 184(1): 285-94. http:\/\/dx.doi.org\/10.1016\/S0014-4886(03) 00250-4 PMID: 14637099","journal-title":"Exp Neurol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S1474-4422(14) 70153-X","volume":"13(8)","author":"Antonini,A.","year":"2014","unstructured":"Antonini,A.; Poewe,W. Adenosi ne A2A receptor antagonists in Parkinson\u2019s disease: still in the running. Lancet Neurol. 2014; 13(8): 748-9. http:\/\/dx.doi.org\/10.1016\/S1474-4422(14) 70153-X PMID: 25008550","journal-title":"Lancet Neurol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/brain\/awh128","volume":"127(Pt 5)","author":"Calon,F.","year":"2004","unstructured":"Calon,F.; Dridi,M.; Hornykiewicz,O.; B\u00e9dard,PJ.; Rajput,AH.; Di Paolo,T. Increased adenosine A2A receptors in the brain of Parkin-son\u2019s disease patients with dyskinesias. Brain. 2004; 127(Pt 5): 1075-84. http:\/\/dx.doi.org\/10.1093\/brain\/awh128 PMID: 15033896","journal-title":"Brain"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S1474-4422(14) 70148-6","volume":"13(8)","author":"Hauser,RA.","year":"2014","unstructured":"Hauser RA, Olanow CW, Kieburtz KD.;et al. Tozadenant (SYN115)  in patients with Parkinson\u2019s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised tri-al. Lancet Neurol. 2014; 13(8): 767-76. http:\/\/dx.doi.org\/10.1016\/S1474-4422(14) 70148-6 PMID: 25008546","journal-title":"Lancet Neurol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ana.21315","volume":"63(3)","author":"LeWitt PA","year":"2008","unstructured":"LeWitt PA, Guttman M, Tetrud JW.;et al. Adenosine A2A receptor antagonist istradefylline (KW-6002)  reduces \u201coff\u201d time in Parkin-son\u2019s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005) . Ann Neurol. 2008; 63(3): 295-302. http:\/\/dx.doi.org\/10.1002\/ana.21315 PMID: 18306243","journal-title":"Ann Neurol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.parkreldis.2011.09.023","volume":"18(2)","author":"Pourcher,E.","year":"2012","unstructured":"Pourcher,E.; Fernandez,HH.; Stacy,M.; Mori,A.; Ballerini,R.; Chaikin,P. Istradefylline for Parkinson\u2019s disease patients experiencing mo-tor fluctuations: results of the KW-6002-US-018 study. Parkinson-ism Relat Disord. 2012; 18(2): 178-84. http:\/\/dx.doi.org\/10.1016\/j.parkreldis.2011.09.023 PMID: 22000279","journal-title":"Parkinson-ism Relat Disord"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-013-0066-7","volume":"73(8)","author":"Dungo,R.","year":"2013","unstructured":"Dungo,R.; Deeks,ED. Istradefylline: first global approval. Drugs. 2013; 73(8): 875-82. http:\/\/dx.doi.org\/10.1007\/s40265-013-0066-7 PMID: 23700273","journal-title":"Drugs"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1080\/14656566.2018.1518433","volume":"19(15)","author":"Takahashi,M.","year":"2018","unstructured":"Takahashi,M.; Fujita,M.; Asai,N.; Saki,M.; Mori,A. Safety and effec-tiveness of istradefylline in patients with Parkinson\u2019s disease: inter-im analysis of a post-marketing surveillance study in Japan. Expert Opin Pharmacother. 2018; 19(15): 1635-42. http:\/\/dx.doi.org\/10.1080\/14656566.2018.1518433 PMID: 30281377","journal-title":"Expert Opin Pharmacother"},{"key":"ref=27","doi-asserted-by":"publisher","author":"Torti,M.","unstructured":"Torti,M.; Vacca,L.; Stocchi,F. Istradefylline for the treatment of Parkinson\u2019s disease: is it a promising strategy? Expert Opin Phar-macother. 2018; 19(16): 1821-8. http:\/\/dx.doi.org\/10.1080\/14656566.2018.1524876 PMID: 30232916","DOI":"10.1080\/14656566.2018.1524876"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/01.NURSE.0000659300.97243.8f","volume":"50","author":"Hussar,DA","year":"2020","unstructured":"Hussar DA. New Drugs 2020, part 1. Nursing. 2020; 50: 31-8. http:\/\/dx.doi.org\/10.1097\/01.NURSE.0000659300.97243.8f","journal-title":"Nursing"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1358\/dot.2020.56.2.3098156","volume":"56(2)","author":"Paton,DM","year":"2020","unstructured":"Paton DM. Istradefylline: adenosine A2A receptor antagonist to reduce \u201cOFF\u201d time in Parkinson\u2019s disease. Drugs Today (Barc). 2020; 56(2): 125-34. http:\/\/dx.doi.org\/10.1358\/dot.2020.56.2.3098156 PMID: 32163528","journal-title":"Drugs Today (Barc)"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF02740748","volume":"12(1)","author":"Blandini,F.","year":"1996","unstructured":"Blandini,F.; Porter,RH.; Greenamyre,JT. Glutamate and Parkinson\u2019s disease. Mol Neurobiol. 1996; 12(1): 73-94. http:\/\/dx.doi.org\/10.1007\/BF02740748 PMID: 8732541","journal-title":"Mol Neurobiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1124\/jpet.300.3.717","volume":"300(3)","author":"Lynch,DR.","year":"2002","unstructured":"Lynch,DR.; Guttmann,RP. Excitotoxicity: perspectives based on N-methyl-D-aspartate receptor subtypes. J Pharmacol Exp Ther. 2002; 300(3): 717-23. http:\/\/dx.doi.org\/10.1124\/jpet.300.3.717 PMID: 11861773","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=32","author":"Koutsilieri,E. .","unstructured":"Koutsilieri,E.; Riederer,P. Excitotoxicity and new antiglutamatergic strategies in Parkinson\u2019s disease and Alzheimer\u2019s disease. Parkin-sonism Relat Disord. 2007; 13(Suppl","journal-title":"Parkin-sonism Relat Disord"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/88404","volume":"4(6)","author":"Vissel,B.","year":"2001","unstructured":"Vissel,B.; Krupp,JJ.; Heineman,n,SF.; Westbrook,GL. A use-dependent tyrosine dephosphorylation of NMDA receptors is inde-pendent of ion flux. Nat Neurosci. 2001; 4(6): 587-96. http:\/\/dx.doi.org\/10.1038\/88404 PMID: 11369939","journal-title":"Nat Neurosci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/archneur.56.11.1383","volume":"56(11)","author":"Metman,LV.","year":"1999","unstructured":"Metman,LV.; Del Dotto,P.; LePoole,K.; Konitsiotis,S.; Fang,J.; Chase,TN. Amantadine for levodopa-induced dyskinesias: a 1-year fol-low-up study. Arch Neurol. 1999; 56(11): 1383-6. http:\/\/dx.doi.org\/10.1001\/archneur.56.11.1383 PMID: 10555659","journal-title":"Arch Neurol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1136\/jnnp-2012-303182","volume":"84(5)","author":"Moreau,C.","year":"2013","unstructured":"Moreau C, Delval A, Tiffreau V.;et al. Memantine for axial signs in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled pilot study. J Neurol Neurosurg Psychiatry. 2013; 84(5): 552-5. http:\/\/dx.doi.org\/10.1136\/jnnp-2012-303182 PMID: 23077087","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.coph.2006.08.011","volume":"7(1)","author":"Paoletti,P.","year":"2007","unstructured":"Paoletti,P.; Neyton,J. NMDA receptor subunits: function and phar-macology. Curr Opin Pharmacol. 2007; 7(1): 39-47. http:\/\/dx.doi.org\/10.1016\/j.coph.2006.08.011 PMID: 17088105","journal-title":"Curr Opin Pharmacol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/mds.10107","volume":"17(3)","author":"Nash,JE.","year":"2002","unstructured":"Nash,JE.; Brotchie,JM. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. Mov Disord. 2002; 17(3): 455-66. http:\/\/dx.doi.org\/10.1002\/mds.10107 PMID: 12112191","journal-title":"Mov Disord"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coph.2005.11.001","volume":"6(1)","author":"Gogas,KR","year":"2006","unstructured":"Gogas KR. Glutamate-based therapeutic approaches: NR2B recep-tor antagonists. Curr Opin Pharmacol. 2006; 6(1): 68-74. http:\/\/dx.doi.org\/10.1016\/j.coph.2005.11.001 PMID: 16376149","journal-title":"Curr Opin Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.neuropharm.2004.03.011","volume":"47(2)","author":"Wessell,RH.","year":"2004","unstructured":"Wessell,RH.; Ahmed,SM.; Menniti,FS.; Dunbar,GL.; Chase,TN.; Oh,JD. NR2B selective NMDA receptor antagonist CP-101,606 pre-vents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology. 2004; 47(2): 184-94. http:\/\/dx.doi.org\/10.1016\/j.neuropharm.2004.03.011 PMID: 15223297","journal-title":"Neuropharmacology"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1006\/exnr.2000.7444","volume":"165(1)","author":"Nash,JE.","year":"2000","unstructured":"Nash JE, Fox SH, Henry B.;et al. Antiparkinsonian actions of ifen-prodil in the MPTP-lesioned marmoset model of Parkinson\u2019s dis-ease. Exp Neurol. 2000; 165(1): 136-42. http:\/\/dx.doi.org\/10.1006\/exnr.2000.7444 PMID: 10964492","journal-title":"Exp Neurol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40263-012-0016-z","volume":"26(12)","author":"Duty,S","year":"2012","unstructured":"Duty S. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson\u2019s disease. CNS Drugs. 2012; 26(12): 1017-32. http:\/\/dx.doi.org\/10.1007\/s40263-012-0016-z PMID: 23114872","journal-title":"CNS Drugs"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/mds.22974","volume":"25(7)","author":"Eggert,K.","year":"2010","unstructured":"Eggert K, Squillacote D, Barone P.;et al. Safety and efficacy of perampanel in advanced Parkinson\u2019s disease: a randomized, place-bo-controlled study. Mov Disord. 2010; 25(7): 896-905. http:\/\/dx.doi.org\/10.1002\/mds.22974 PMID: 20461807","journal-title":"Mov Disord"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.parkreldis.2014.01.016","volume":"20(4)","author":"Kobylecki,C.","year":"2014","unstructured":"Kobylecki,C.; Burn,DJ.; Kass-Iliyya,L.; Kellett,MW.; Crossman,AR.; Silverdale,MA. Randomized clinical trial of topiramate for levodo-pa-induced dyskinesia in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014; 20(4): 452-5. http:\/\/dx.doi.org\/10.1016\/j.parkreldis.2014.01.016 PMID: 24521874","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nrn1763","volume":"6(10)","author":"Conn,PJ.","year":"2005","unstructured":"Conn,PJ.; Battaglia,G.; Marino,MJ.; Nicoletti,F. Metabotropic gluta-mate receptors in the basal ganglia motor circuit. Nat Rev Neurosci. 2005; 6(10): 787-98. http:\/\/dx.doi.org\/10.1038\/nrn1763 PMID: 16276355","journal-title":"Nat Rev Neurosci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/mds.25920","volume":"29(8)","author":"Bezard,E.","year":"2014","unstructured":"Bezard E, Pioli EY, Li Q.;et al. The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Mov Disord. 2014; 29(8): 1074-9. http:\/\/dx.doi.org\/10.1002\/mds.25920 PMID: 24865335","journal-title":"Mov Disord"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/mds.25561","volume":"28(13)","author":"Stocchi,F.","year":"2013","unstructured":"Stocchi F, Rascol O, Destee A.;et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord. 2013; 28(13): 1838-46. http:\/\/dx.doi.org\/10.1002\/mds.25561 PMID: 23853029","journal-title":"Mov Disord"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/mds.26659","volume":"31(9)","author":"Tison,F.","year":"2016","unstructured":"Tison F, Keywood C, Wakefield M.;et al. A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levo-dopa-induced dyskinesia in Parkinson\u2019s disease. Mov Disord. 2016; 31(9): 1373-80. http:\/\/dx.doi.org\/10.1002\/mds.26659 PMID: 27214664","journal-title":"Mov Disord"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1517\/13543784.2014.931370","volume":"23(8)","author":"Petrov,D.","year":"2014","unstructured":"Petrov D, Pedros I, de Lemos ML.;et al. Mavoglurant as a treat-ment for Parkinson\u2019s disease. Expert Opin Investig Drugs. 2014; 23(8): 1165-79. http:\/\/dx.doi.org\/10.1517\/13543784.2014.931370 PMID: 24960254","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3109\/00207454.2013.841685","volume":"126(1)","author":"Kumar,R.","year":"2016","unstructured":"Kumar R, Hauser RA, Mostillo J.;et al. Mavoglurant (AFQ056)  in combination with increased levodopa dosages in Parkinson\u2019s dis-ease patients. Int J Neurosci. 2016; 126(1): 20-4. http:\/\/dx.doi.org\/10.3109\/00207454.2013.841685 PMID: 24007304","journal-title":"Int J Neurosci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41401-020-0380-z","volume":"41(4)","author":"Liu,C","year":"2020","unstructured":"Liu C. Targeting the cholinergic system in Parkinson\u2019s disease. Acta Pharmacol Sin. 2020; 41(4): 453-63. http:\/\/dx.doi.org\/10.1038\/s41401-020-0380-z PMID: 32132659","journal-title":"Acta Pharmacol Sin"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2019.02.019","volume":"126","author":"Ztaou,S.","year":"2019","unstructured":"Ztaou,S.; Amalric,M. Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson\u2019s disease. Neurochem Int. 2019; 126: 1-10. http:\/\/dx.doi.org\/10.1016\/j.neuint.2019.02.019 PMID: 30825602","journal-title":"Neurochem Int"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/mds.27740","volume":"34(8)","author":"Moehle,MS.","year":"2019","unstructured":"Moehle,MS.; Conn,PJ. Roles of the M 4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders. Mov Dis-ord. 2019; 34(8): 1089-99. http:\/\/dx.doi.org\/10.1002\/mds.27740 PMID: 31211471","journal-title":"Mov Dis-ord"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/archneur.1982.00510220064017","volume":"39(10)","author":"Sadeh,M.","year":"1982","unstructured":"Sadeh,M.; Braham,J.; Modan,M. Effects of anticholinergic drugs on memory in Parkinson\u2019s disease. Arch Neurol. 1982; 39(10): 666-7. http:\/\/dx.doi.org\/10.1001\/archneur.1982.00510220064017 PMID: 7125982","journal-title":"Arch Neurol"},{"key":"ref=54","first-page":"39","volume":"2(2)","author":"Brocks,DR","year":"1999","unstructured":"Brocks DR. Anticholinergic drugs used in Parkinson\u2019s disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci. 1999; 2(2): 39-46. PMID: 10952768","journal-title":"J Pharm Pharm Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.neuroscience.2019.04.008","volume":"409","author":"Chambers,NE.","year":"2019","unstructured":"Chambers NE, Meadows SM, Taylor A.;et al. Effects of muscarinic acetylcholine m1 and m4 receptor blockade on dyskinesia in the Hemi-Parkinsonian Rat. Neuroscience. 2019; 409: 180-94. http:\/\/dx.doi.org\/10.1016\/j.neuroscience.2019.04.008 PMID: 31029732","journal-title":"Neuroscience"},{"key":"ref=56","author":"Kish SJ","unstructured":"Kish SJ. Biochemistry of Parkinson\u2019s disease: is a brain sero-tonergic deficiency a characteristic of idiopathic Parkinson\u2019s dis-ease? Adv Neurol. 2003; 91: 39-49. PMID: 12442662"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/brain\/awm082","volume":"130(Pt 7)","author":"Carta,M.","year":"2007","unstructured":"Carta,M.; Carlsson,T.; Kirik,D.; Bj\u00f6rklund,A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain. 2007; 130(Pt 7): 1819-33. http:\/\/dx.doi.org\/10.1093\/brain\/awm082 PMID: 17452372","journal-title":"Brain"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1172\/JCI71640","volume":"124(3)","author":"Politis,M.","year":"2014","unstructured":"Politis M, Wu K, Loane C.;et al. Serotonergic mechanisms respon-sible for levodopa-induced dyskinesias in Parkinson\u2019s disease pa-tients. J Clin Invest. 2014; 124(3): 1340-9. http:\/\/dx.doi.org\/10.1172\/JCI71640 PMID: 24531549","journal-title":"J Clin Invest"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/00002826-200403000-00003","volume":"27(2)","author":"Olanow,CW.","year":"2004","unstructured":"Olanow CW, Damier P, Goetz CG.;et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study) . Clin Neuropharmacol. 2004; 27(2): 58-62. http:\/\/dx.doi.org\/10.1097\/00002826-200403000-00003 PMID: 15252265","journal-title":"Clin Neuropharmacol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/mds.25366","volume":"28(8)","author":"Bezard,E.","year":"2013","unstructured":"Bezard E, Tronci E, Pioli EY.;et al. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyski-nesia. Mov Disord. 2013; 28(8): 1088-96. http:\/\/dx.doi.org\/10.1002\/mds.25366 PMID: 23389842","journal-title":"Mov Disord"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11910-013-0409-5","volume":"13(12)","author":"Marsh,L","year":"2013","unstructured":"Marsh L. Depression and Parkinson\u2019s disease: current knowledge. Curr Neurol Neurosci Rep. 2013; 13(12): 409. http:\/\/dx.doi.org\/10.1007\/s11910-013-0409-5 PMID: 24190780","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/mds.22586","volume":"24(9)","author":"Menza,M.","year":"2009","unstructured":"Menza M, Dobkin RD, Marin H.;et al. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson\u2019s disease. Mov Disord. 2009; 24(9): 1325-32. http:\/\/dx.doi.org\/10.1002\/mds.22586 PMID: 19412944","journal-title":"Mov Disord"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/mds.23895","volume":"27(1)","author":"Ballanger,B.","year":"2012","unstructured":"Ballanger B, Klinger H, Eche J.;et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson\u2019s dis-ease. Mov Disord. 2012; 27(1): 84-9. http:\/\/dx.doi.org\/10.1002\/mds.23895 PMID: 21994070","journal-title":"Mov Disord"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","volume":"78(16)","author":"Richard,IH.","year":"2012","unstructured":"Richard IH, McDermott MP, Kurlan R.;et al. A randomized, dou-ble-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012; 78(16): 1229-36. http:\/\/dx.doi.org\/10.1212\/WNL.0b013e3182516244 PMID: 22496199","journal-title":"Neurology"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.brainres.2010.12.015","volume":"1373","author":"McMillan PJ","year":"2011","unstructured":"McMillan PJ, White SS, Franklin A.;et al. Differential response of the central noradrenergic nervous system to the loss of locus co-eruleus neurons in Parkinson\u2019s disease and Alzheimer\u2019s disease. Brain Res. 2011; 1373: 240-52. http:\/\/dx.doi.org\/10.1016\/j.brainres.2010.12.015 PMID: 21147074","journal-title":"Brain Res"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0149-7634(00) 00028-2","volume":"24(6)","author":"Gesi,M.","year":"2000","unstructured":"Gesi,M.; Soldani,P.; Giorgi,FS.; Santinami,A.; Bonaccorsi,I.; Fornai,F. The role of the locus coeruleus in the development of Parkinson\u2019s disease. Neurosci Biobehav Rev. 2000; 24(6): 655-68. http:\/\/dx.doi.org\/10.1016\/S0149-7634(00) 00028-2 PMID: 10940440","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=67","author":"Rommelfanger,KS.","unstructured":"Rommelfanger,KS.; Edwards,GL.; Freeman,KG.; Liles,LC.; Miller,GW.; Weinshenker,D. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci USA 2007; 104(34): 13804-9. http:\/\/dx.doi.org\/10.1073\/pnas.0702753104 PMID: 17702867.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/mds.1143","volume":"16(4)","author":"Rascol,O.","year":"2001","unstructured":"Rascol O, Arnulf I, Peyro-Saint Paul H.;et al. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Par-kinson\u2019s disease. Mov Disord. 2001; 16(4): 708-13. http:\/\/dx.doi.org\/10.1002\/mds.1143 PMID: 11481696","journal-title":"Mov Disord"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1002\/mds.23172","volume":"25(13)","author":"Johnston,TH.","year":"2010","unstructured":"Johnston,TH.; Fox,SH.; Piggott,MJ.; Savola,JM.; Brotchie,JM. The a 2 adrenergic antagonist fipamezole improves quality of levodopa ac-tion in Parkinsonian primates. Mov Disord. 2010; 25(13): 2084-93. http:\/\/dx.doi.org\/10.1002\/mds.23172 PMID: 20824735","journal-title":"Mov Disord"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1212\/WNL.0b013e31825f0451","volume":"79(2)","author":"Lewitt,PA.","year":"2012","unstructured":"Lewitt PA, Hauser RA, Lu M.;et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study) . Neurology. 2012; 79(2): 163-9. http:\/\/dx.doi.org\/10.1212\/WNL.0b013e31825f0451 PMID: 22744665","journal-title":"Neurology"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"6693","DOI":"10.1523\/JNEUROSCI.18-17-06693.1998","volume":"18(17)","author":"Bonci,A.","year":"1998","unstructured":"Bonci,A.; Grillner,P.; Mercuri,NB.; Bernardi,G. L-Type calcium channels mediate a slow excitatory synaptic transmission in rat midbrain dopaminergic neurons. J Neurosci. 1998; 18(17): 6693-703. http:\/\/dx.doi.org\/10.1523\/JNEUROSCI.18-17-06693.1998 PMID: 9712641","journal-title":"J Neurosci"},{"key":"ref=72","author":"Striessnig,J.","unstructured":"Striessnig J, Koschak A, Sinnegger-Brauns MJ.;et al. Role of. t-age-gated L-type Ca2+ channel isoforms for brain function. Bio-chem Soc Trans. 2006; 34(Pt 5): 903-9. http:\/\/dx.doi.org\/10.1042\/BST0340903 PMID: 17052224"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00441-004-0972-9","volume":"318(1)","author":"Stark,AK.","year":"2004","unstructured":"Stark,AK.; Pakkenberg,B. Histological changes of the dopaminergic nigrostriatal system in aging. Cell Tissue Res. 2004; 318(1): 81-92. http:\/\/dx.doi.org\/10.1007\/s00441-004-0972-9 PMID: 15365813","journal-title":"Cell Tissue Res"},{"key":"ref=74","author":"Chan,CS.","unstructured":"Chan,CS.; Gertler,TS.; Surmeier,DJ. A molecular basis for the in-creased vulnerability of substantia nigra dopamine neurons in aging and Parkinson\u2019s disease. Mov Disord. 2010; 25(Suppl","journal-title":"Mov Disord"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev.genet.39.110304.095751","volume":"39","author":"Wallace,DC","year":"2005","unstructured":"Wallace DC. A mitochondrial paradigm of metabolic and degen-erative diseases, aging, and cancer: a dawn for evolutionary medi-cine. Annu Rev Genet. 2005; 39: 359-407. http:\/\/dx.doi.org\/10.1146\/annurev.genet.39.110304.095751 PMID: 16285865","journal-title":"Annu Rev Genet"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.nbd.2011.04.007","volume":"43(2)","author":"Ilijic,E.","year":"2011","unstructured":"Ilijic,E.; Guzman,JN.; Surmeier,DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson\u2019s dis-ease. Neurobiol Dis. 2011; 43(2): 364-71. http:\/\/dx.doi.org\/10.1016\/j.nbd.2011.04.007 PMID: 21515375","journal-title":"Neurobiol Dis"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1002\/mds.23308","volume":"25(16)","author":"Simuni,T.","year":"2010","unstructured":"Simuni T, Borushko E, Avram MJ.;et al. Tolerability of isradipine in early Parkinson\u2019s disease: a pilot dose escalation study. Mov Disord. 2010; 25(16): 2863-6. http:\/\/dx.doi.org\/10.1002\/mds.23308 PMID: 20818667","journal-title":"Mov Disord"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrn1883","volume":"7(4)","author":"Youdim,MB.","year":"2006","unstructured":"Youdim,MB.; Edmondson,D.; Tipton,KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006; 7(4): 295-309. http:\/\/dx.doi.org\/10.1038\/nrn1883 PMID: 16552415","journal-title":"Nat Rev Neurosci"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.neulet.2003.10.067","volume":"355(3)","author":"Bar,Am,O","year":"2004","unstructured":"Bar Am,O.; Amit,T.; Youdim,MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett. 2004; 355(3): 169-72. http:\/\/dx.doi.org\/10.1016\/j.neulet.2003.10.067 PMID: 14732458","journal-title":"Neurosci Lett"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s40263-014-0206-y","volume":"28(11)","author":"McCormack PL","year":"2014","unstructured":"McCormack PL. Rasagiline: a review of its use in the treatment of idiopathic Parkinson\u2019s disease. CNS Drugs. 2014; 28(11): 1083-97. http:\/\/dx.doi.org\/10.1007\/s40263-014-0206-y PMID: 25322951","journal-title":"CNS Drugs"},{"key":"ref=81","first-page":"23","volume":"4(1)","author":"Nayak,L.","year":"2008","unstructured":"Nayak,L.; Henchcliffe,C. Rasagiline in treatment of Parkinson\u2019s disease. Neuropsychiatr Dis Treat. 2008; 4(1): 23-32. PMID: 18728823","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=82","first-page":"413","volume":"5(4)","author":"Malaty,IA.","year":"2009","unstructured":"Malaty,IA.; Fernandez,HH. Role of rasagiline in treating Parkin-son\u2019s disease: effect on disease progression. Ther Clin Risk Manag. 2009; 5(4): 413-9. PMID: 19753135","journal-title":"Ther Clin Risk Manag"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1517\/17425255.2013.781152","volume":"9(5)","author":"T\u00e1bi,T.","year":"2013","unstructured":"T\u00e1bi,T.; Sz\u00f6ko,E.; V\u00e9csei,L.; Magya,r,K. The pharmacokinetic evalu-ation of selegiline ODT for the treatment of Parkinson\u2019s disease. Expert Opin Drug Metab Toxicol. 2013; 9(5): 629-36. http:\/\/dx.doi.org\/10.1517\/17425255.2013.781152 PMID: 23506388","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/ana.410400605","volume":"40(6)","author":"Olanow,CW.","year":"1996","unstructured":"Olanow,CW.; Fahn,S.; Langston,JW.; Godbold,J. Selegiline and mortality in Parkinson\u2019s disease. Ann Neurol. 1996; 40(6): 841-5. http:\/\/dx.doi.org\/10.1002\/ana.410400605 PMID: 9007088","journal-title":"Ann Neurol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ana.410410223","volume":"41(2)","author":"Lees,AJ.","year":"1997","unstructured":"Lees,AJ.; Head,J.; Shlomo,YB. Selegiline and mortality in Parkin-son\u2019s disease: another view. Ann Neurol. 1997; 41(2): 282-3. http:\/\/dx.doi.org\/10.1002\/ana.410410223 PMID: 9029081","journal-title":"Ann Neurol"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2174\/1871527314666150325235608","volume":"14","author":"Sari,Y. .","year":"2015","unstructured":"Sari,Y.; Khalil,A. Monoamine oxidase inhibitors extracted from tobacco smoke as neuroprotective factors for potential treatment of Parkinson's disease. CNS Neurol Disord Drug Targets. 2015; 14: 777-85","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"124","DOI":"10.5607\/en.2014.23.2.124","volume":"23(2)","author":"Jung,UJ.","year":"2014","unstructured":"Jung,UJ.; Leem,E.; Kim,SR. Naringin: a protector of the nigrostriatal dopaminergic projection. Exp Neurobiol. 2014; 23(2): 124-9. http:\/\/dx.doi.org\/10.5607\/en.2014.23.2.124 PMID: 24963276","journal-title":"Exp Neurobiol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0891-0618(01) 00115-6","volume":"21(4)","author":"Chauhan,NB.","year":"2001","unstructured":"Chauhan,NB.; Siegel,GJ.; Lee,JM. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkin-son\u2019s disease brain. J Chem Neuroanat. 2001; 21(4): 277-88. http:\/\/dx.doi.org\/10.1016\/S0891-0618(01) 00115-6 PMID: 11429269","journal-title":"J Chem Neuroanat"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.3390\/ijms18102190","volume":"18(10)","author":"Torres,N.","year":"2017","unstructured":"Torres,N.; Molet,J.; Moro,C.; Mitrofanis,J.; Benabid,AL. Neuropro-tective surgical strategies in Parkinson\u2019s disease: role of preclinical data. Int J Mol Sci. 2017; 18(10): 2190","journal-title":"Int J Mol Sci"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1126\/science.275.5301.838","volume":"275(5301)","author":"Choi-Lundberg DL","year":"1997","unstructured":"Choi-Lundberg DL, Lin Q, Chang Y-N.;et al. Dopaminergic neu-rons protected from degeneration by GDNF gene therapy. Science. 1997; 275(5301): 838-41. http:\/\/dx.doi.org\/10.1126\/science.275.5301.838 PMID: 9012352","journal-title":"Science"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0306-4522(97) 83045-X","volume":"78(1)","author":"Lapchak,PA.","year":"1997","unstructured":"Lapchak,PA.; Miller,PJ.; Collins,F.; Jiao,S. Glial cell line-derived neurotrophic factor attenuates be havioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricu-lar and intranigral delivery. Neuroscience. 1997; 78(1): 61-72. http:\/\/dx.doi.org\/10.1016\/S0306-4522(97) 83045-X PMID: 9135089","journal-title":"Neuroscience"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/S0006-8993(96) 01265-6","volume":"747(1)","author":"Lapchak,PA.","year":"1997","unstructured":"Lapchak,PA.; Jiao,S.; Collins,F.; Miller,PJ. Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat fol-lowing a bolus intraventricular injection. Brain Res. 1997; 747(1): 92-102. http:\/\/dx.doi.org\/10.1016\/S0006-8993(96) 01265-6 PMID: 9042532","journal-title":"Brain Res"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/00001756-199807130-00039","volume":"9(10)","author":"Date,I.","year":"1998","unstructured":"Date,I.; Aoi,M.; Tomita,S.; Collins,F.; Ohmoto,TJN. GDNF admin-istration induces recovery of the nigrostriatal dopaminergic system both in young and aged parkinsonian mice. Neuroreport. 1998; 9(10): 2365-9","journal-title":"Neuroreport"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/373335a0","volume":"373(6512)","author":"Tomac,A.","year":"1995","unstructured":"Tomac A, Lindqvist E, Lin L-F.;et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 1995; 373(6512): 335-9","journal-title":"Nature"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/brain\/awf234","volume":"125(Pt 10)","author":"Grondin,R.","year":"2002","unstructured":"Grondin R, Zhang Z, Yi A.;et al. Chronic, controlled GDNF infu-sion promotes structural and functional recovery in advanced par-kinsonian monkeys. Brain. 2002; 125(Pt 10): 2191-201","journal-title":"Brain"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1093\/brain\/awr149","volume":"134(Pt 8)","author":"Decressac,M.","year":"2011","unstructured":"Decressac M, Ulusoy A, Mattsson B.;et al. GDNF fails to exert neuroprotection in a rat a-synuclein model of Parkinson\u2019s disease. Brain. 2011; 134(Pt 8): 2302-11","journal-title":"Brain"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"163ra156","DOI":"10.1126\/scitranslmed.3004676","volume":"4(163)","author":"Decressac,M.","year":"2012","unstructured":"Decressac,M.; Kadkhodaei,B.; Mattss,on,B.; Laguna,A.; Perlmann,T.; Bj\u00f6rklund,A. a-Synuclein\u2013induced down-regulation of Nurr1 dis-rupts GDNF signaling in nigral dopamine neurons. Sci Transl Med. 2012; 4(163): 163ra156","journal-title":"Sci Transl Med"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1523\/JNEUROSCI.18-13-04929.1998","volume":"18(13)","author":"Horger,BA.","year":"1998","unstructured":"Horger BA, Nishimura MC, Armanini MP.;et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci. 1998; 18(13): 4929-37","journal-title":"J Neurosci"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0006-8993(02) 02934-7","volume":"947(2)","author":"Oiwa,Y.","year":"2002","unstructured":"Oiwa,Y.; Yoshimura,R.; Nakai,K.; Itakura,T. Dopaminergic neuro-protection and regeneration by neurturin assessed by using behav-ioral, biochemical and histochemical measurements in a model of progressive Parkinson\u2019s disease. Brain Res. 2002; 947(2): 271-83. http:\/\/dx.doi.org\/10.1016\/S0006-8993(02) 02934-7 PMID: 12176170","journal-title":"Brain Res"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1179\/016164103101201472","volume":"25(3)","author":"Li,H.","year":"2003","unstructured":"Li H, He Z, Su T.;et al. Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in a rhesus monkey model of Parkinson's disease. Neurol Res. 2003; 25(3): 263-7","journal-title":"Neurol Res"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"e0188239","DOI":"10.1371\/journal.pone.0188239","volume":"12(11)","author":"Reyes-Corona D","year":"2017","unstructured":"Reyes-Corona D, Vazquez-Hernandez N, Escobedo L.;et al. Neurturin overexpression in dopaminergic neurons induces presyn-aptic and postsynaptic structural changes in rats with chronic 6-hydroxydopamine lesion. PLoS One. 2017; 12(11): e0188239","journal-title":"PLoS One"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2013.04.011","volume":"58","author":"Herzog,CD.","year":"2013","unstructured":"Herzog CD, Brown L, Kruegel BR.;et al. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal deliv ery of AAV2-NRTN (CERE-120) . Neu-robiol Dis. 2013; 58: 38-48","journal-title":"Neu-robiol Dis"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nbd.2007.04.003","volume":"27","author":"Gasmi,M.","year":"2007","unstructured":"Gasmi M, Brandon EP, Herzog CD.;et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term effica-cy and tolerability of CERE-120 for Parkinson\u2019s disease. Neurobiol Dis. 2007; 27: 67-76","journal-title":"Neurobiol Dis"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.expneurol.2005.03.006","volume":"195(1)","author":"Fjord-Larsen L","year":"2005","unstructured":"Fjord-Larsen L, Johansen JL, Kusk P.;et al. Efficient in vivo pro-tection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp Neurol. 2005; 195(1): 49-60","journal-title":"Exp Neurol"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/mt.2008.170","volume":"16(10)","author":"Herzog,CD.","year":"2008","unstructured":"Herzog CD, Dass B, Gasmi M.;et al. Transgene expression, bioac-tivity, and safety of CERE-120 (AAV2-neurturin)  following deliv-ery to the monkey striatum. Mol Ther. 2008; 16(10): 1737-44","journal-title":"Mol Ther"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"7810","DOI":"10.1523\/JNEUROSCI.15-12-07810.1995","volume":"15(12)","author":"Levivier,M.","year":"1995","unstructured":"Levivier,M.; Przedborski,S.; Bencsics,C.; Kang,UJ. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson\u2019s disease. J Neurosci. 1995; 15(12): 7810-20. http:\/\/dx.doi.org\/10.1523\/JNEUROSCI.15-12-07810.1995 PMID: 8613721","journal-title":"J Neurosci"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0006-8993(95) 00596-I","volume":"691(1-2)","author":"Yoshimoto,Y.","year":"1995","unstructured":"Yoshimoto,Y.; Lin,Q.; Collier,TJ.; Frim,DM.; Breakefield,XO.; Bohn,MC. Astrocytes retrovirally transduced with BDNF elicit behavior-al improvement in a rat model of Parkinson\u2019s disease. Brain Res. 1995; 691(1-2): 25-36. http:\/\/dx.doi.org\/10.1016\/0006-8993(95) 00596-I PMID: 8590062","journal-title":"Brain Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0006-8993(99) 02116-2","volume":"847(2)","author":"Klein,RL.","year":"1999","unstructured":"Klein,RL.; Lewis,MH.; Muzyczka,N.; Meyer,EM. Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Res. 1999; 847(2): 314-20. http:\/\/dx.doi.org\/10.1016\/S0006-8993(99) 02116-2 PMID: 10575102","journal-title":"Brain Res"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.brainres.2005.05.072","volume":"1052(2)","author":"Sun,M.","year":"2005","unstructured":"Sun,M.; Kong,L.; Wang,X.; Lu,XG.; Gao,Q.; Geller,AI. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson\u2019s disease. Brain Res. 2005; 1052(2): 119-29. http:\/\/dx.doi.org\/10.1016\/j.brainres.2005.05.072 PMID: 16018990","journal-title":"Brain Res"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/0306-4522(96)00152-2","volume":"74(3)","author":"Funa,K.","year":"1996","unstructured":"Funa K, Yamada N, Brodin G.;et al. Enhanced synthesis of plate-let-derived growth factor following injury induced by 6-hydroxydopamine in rat brain. Neuroscience. 1996; 74(3): 825-33","journal-title":"Neuroscience"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.nbd.2016.06.002","volume":"94","author":"Padel,T.","year":"2016","unstructured":"Padel T, \u00d6zen I, Boix J.;et al. Platelet-derived growth factor-BB has neurorestorative effects and modulates the pericyte response in a partial 6-hydroxydopamine lesion mouse model of Parkinson's disease. Neurobiol Dis. 2016; 94: 95-105","journal-title":"Neurobiol Dis"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JPD-2011-0003","volume":"1(1)","author":"Zachrisson,O.","year":"2011","unstructured":"Zachrisson O, Zhao M, Andersson A.;et al. Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease. J Parkinsons Dis. 2011; 1(1): 49-63","journal-title":"J Parkinsons Dis"},{"key":"ref=113","author":"Voutilainen,MH.","unstructured":"Voutilainen MH, B\u00e4ck S, Per\u00e4nen J.;et al. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkin-son's disease. 2011; 228: 98-108","journal-title":"2011; 228: 98-108"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3727\/096368911X600948","volume":"21(6)","author":"Airavaara,M.","year":"2012","unstructured":"Airavaara M, Harvey BK, Voutilainen MH.;et al. CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplant. 2012; 21(6): 1213-23","journal-title":"Cell Transplant"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.expneurol.2013.06.002","volume":"248","author":"Ren,X.","year":"2013","unstructured":"Ren,X.; Zhang,T.; Gong,X.; Hu,G.; Ding,W.; Wang,XJEn. AAV2-mediated striatum delivery of human CDNF prevents the deteriora-tion of midbrain dopamine neurons in a 6-hydroxydopamine in-duced parkinsonian rat model. Exp Neurol. 2013; 248: 148-56","journal-title":"Exp Neurol"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/mt.2014.206","volume":"23","author":"Cordero-Llana \u00e0","year":"2015","unstructured":"Cordero-Llana \u00d3, Houghton BC, Rinaldi F.;et al. Enhanced effica-cy of the CDNF\/MANF family by combined intranigral overex-pression in the 6-OHDA rat model of Parkinson's disease. Mol Ther. 2015; 23: 244-54","journal-title":"Mol Ther"},{"key":"ref=117","first-page":"ENEURO.0117","volume":"4(1)","author":"Voutilainen,MH.","year":"2017","unstructured":"Voutilainen MH, De Lorenzo F, Stepanova P.;et al. Evidence for an additive neurorestorative effect of simultaneously administered CDNF and GDNF in hemiparkinsonian rats: implications for dif-ferent mechanism of action. eNeuro. 2017; 4(1): ENEURO.0117-16.2017","journal-title":"eNeuro"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40266-014-0160-x","volume":"31(4)","author":"Rodrigues,TM.","year":"2014","unstructured":"Rodrigues,TM.; Jer\u00f3nimo-Santos,A.; Outeiro,TF.; Sebasti\u00e3o,AM.; Di\u00f3genes,MJ. Challenges and promises in the development of neu-rotrophic factor-based therapies for Parkinson\u2019s disease. Drugs Ag-ing. 2014; 31(4): 239-61. http:\/\/dx.doi.org\/10.1007\/s40266-014-0160-x PMID: 24610720","journal-title":"Drugs Ag-ing"},{"key":"ref=119","author":"Kn\u00fcsel B","unstructured":"Kn\u00fcsel B, Winslow JW, Rosenthal A.;et al. Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3. Proc Natl Acad Sci USA 1991; 88(3): 961-5. http:\/\/dx.doi.org\/10.1073\/pnas.88.3.961 PMID: 1992488","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S0006-8993(02) 03222-5","volume":"952(1)","author":"Lorigados,Pedre,L.","year":"2002","unstructured":"Lorigados Pedre L, Pav\u00f3n Fuentes N, Alvarez Gonz\u00e1lez L.;et al. Nerve growth factor levels in Parkinson disease and experimental parkinsonian rats. Brain Res. 2002; 952(1): 122-7. http:\/\/dx.doi.org\/10.1016\/S0006-8993(02) 03222-5 PMID: 12363411","journal-title":"Brain Res"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0304-3940(99) 00463-2","volume":"270(1)","author":"Mogi,M.","year":"1999","unstructured":"Mogi M, Togari A, Kondo T.;et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the sub-stantia nigra in Parkinson\u2019s disease. Neurosci Lett. 1999; 270(1): 45-8. http:\/\/dx.doi.org\/10.1016\/S0304-3940(99) 00463-2 PMID: 10454142","journal-title":"Neurosci Lett"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.brainres.2008.11.097","volume":"1256","author":"Eliash,S.","year":"2009","unstructured":"Eliash,S.; Dror,V.; Cohen,S.; Re,havi,M. Neuroprotection by rasa-giline in thiamine deficient rats. Brain Res. 2009; 1256: 138-48. http:\/\/dx.doi.org\/10.1016\/j.brainres.2008.11.097 PMID: 19103184","journal-title":"Brain Res"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00702-011-0730-6","volume":"119(4)","author":"Inaba-Hasegawa,K.","year":"2012","unstructured":"Inaba-Hasegawa,K.; Akao,Y.; Maru,yama,W.; Naoi,M. Type A mon-oamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase. J Neural Transm (Vienna). 2012; 119(4): 405-14. http:\/\/dx.doi.org\/10.1007\/s00702-011-0730-6 PMID: 22065207","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.2174\/138161210793176527","volume":"16(25)","author":"Naoi,M.","year":"2010","unstructured":"Naoi,M.; Maruyama,W. Monoamine oxidase inhibitors as neuropro-tective agents in age-dependent neurodegenerative disorders. Curr Pharm Des. 2010; 16(25): 2799-817. http:\/\/dx.doi.org\/10.2174\/138161210793176527 PMID: 20698822","journal-title":"Curr Pharm Des"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1586\/ern.13.60","volume":"13(6)","author":"Naoi,M.","year":"2013","unstructured":"Naoi,M.; Maruyama,W.; Inaba-H,asegawa,K. Revelation in the neu-roprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms. Expert Rev Neurother. 2013; 13(6): 671-84. http:\/\/dx.doi.org\/10.1586\/ern.13.60 PMID: 23739004","journal-title":"Expert Rev Neurother"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.pneurobio.2010.06.008","volume":"92(3)","author":"Weinreb,O.","year":"2010","unstructured":"Weinreb,O.; Amit,T.; Bar-Am,O.; Youdim,MB. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuropro-tective activity. Prog Neurobiol. 2010; 92(3): 330-44. http:\/\/dx.doi.org\/10.1016\/j.pneurobio.2010.06.008 PMID: 20600573","journal-title":"Prog Neurobiol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0014-2999(96) 00593-6","volume":"315(1)","author":"Semkova,I.","year":"1996","unstructured":"Semkova,I.; Wolz,P.; Schilling,M.; Krieglstein,J. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur J Pharmacol. 1996; 315(1): 19-30. http:\/\/dx.doi.org\/10.1016\/S0014-2999(96) 00593-6 PMID: 8960860","journal-title":"Eur J Pharmacol"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/182256","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/182256\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/182256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T19:26:05Z","timestamp":1615577165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/182256\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":127,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527319666200525011110","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}